Frank Jessen
Early diagnosis of Alzheimer's disease
Prof. Dr. Frank Jessen
Cooperation Unit Leader Cologne
Kerpenerst. 62
50924  Köln
 +49 221 478-4010

Areas of investigation/research focus

Frank Jessen’s focuses on early detection of Alzheimer’s disease (AD) in patients. A particular focus is on clinical and neuropsychological assessment as well as on MR-imaging. Frank Jessen is leading international initiatives to conceptualize very first signs of AD, such as subjective cognitive decline (SCD). In that context, he is the coordinator of the multisite DELCODE study of the DZNE. Within DELCODE, patients from memory centers are sampled and followed longitudinally with the aim of improving disease course prediction and of developing new disease markers. Together with Michael Wagner, he is heading the clinical and neuropsychological assessment core of the DZNE clinical research section.

He is also strongly engaged in clinical trials in AD and he is the main author of the German guidelines on the diagnosis, treatment and prevention of dementia.

He serves on several boards, including the steering committee of the European Alzheimer’s Disease Consortium (EADC), the National Institute in Aging-Alzheimer’s Association (NIA-AA) working group for the development of the criteria of Alzheimer’s disease and on the ISTAART advisory council.

Key Publications

Laura A. Rabin, Colette M. Smart, Paul K. Crane, Rebecca E. Amariglio, Lorin M. Berman, Mercé Boada, Rachel F. Buckley, Gaël Chételat, Bruno Dubois, Kathryn A. Ellis, Katherine A. Gifford, Angela L. Jefferson, Frank Jessen, Mindy J. Katz, Richard B. Lipton, Tobias Luck, Paul Maruff, Michelle M. Mielke, José Luis Molinuevo, Farnia Naeem, Audrey Perrotin, Ronald C. Petersen, Lorena Rami, Barry Reisberg, Dorene M. Rentz, Steffi G. Riedel-Heller, Shannon L. Risacher, Octavio Rodriguez, Perminder S. Sachdev, Andrew J. Saykin, Melissa J. Slavin, Beth E. Snitz, Reisa A. Sperling, Caroline Tandetnik, Wiesje M. Van Der Flier, Michael Wagner, Steffen Wolfsgruber, Sietske A.M. Sikkes. Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. Journal of Alzheimer's Disease. 2015 Sep 23; 48:S63-S86. doi: 10.3233/JAD-150154
Bengt Winblad, Philippe Amouyel, Sandrine Andrieu, Clive Ballard, Carol Brayne, Henry Brodaty, Angel Cedazo-Minguez, Bruno Dubois, David Edvardsson, Howard Feldman, Laura Fratiglioni, Giovanni B. Frisoni, Serge Gauthier, Jean Georges, Caroline Graff, Khalid Iqbal, Frank Jessen, Gunilla Johansson, Linus Jönsson, Miia Kivipelto, Martin Knapp, Francesca Mangialasche, René Melis, Agneta Nordberg, Marcel Olde Rikkert, Chengxuan Qiu, Thomas P. Sakmar, Philip Scheltens, Lon S. Schneider, Reisa Sperling, Lars O. Tjernberg, Gunhild Waldemar, Anders Wimo, Henrik Zetterberg. Defeating Alzheimer's disease and other dementias: A priority for European science and society. The Lancet Neurology. 2016 Mar 31; 15:455-532. doi: 10.1016/S1474-4422(16)00062-4
Wagner M, Jessen F. Amyloid Pathology, Cognitive Impairment, and Alzheimer Disease Risk. JAMA. 2015 Sep 15; 314:1177. doi: 10.1001/jama.2015.9716
Stefanie Heilmann, Dmitriy Drichel, Jordi Clarimon, Victoria Fernández, André Lacour, Holger Wagner, Mathias Thelen, Isabel Hernández, Juan Fortea, Montserrat Alegret, Rafael Blesa, Ana Mauleón, Maitée Rosende Roca, Johannes Kornhuber, Oliver Peters, Reinhard Heun, Lutz Frölich, Michael Hüll, Michael T. Heneka, Eckart Rüther, Steffi Riedel-Heller, Martin Scherer, Jens Wiltfang, Frank Jessen, Tim Becker, Lluís Tárraga, Mercè Boada, Wolfgang Maier, Alberto Lleó, Agustin Ruiz, Markus M. Nöthen, Alfredo Ramirez. PLD3 in non-familial Alzheimer's disease. Nature. 2015 Apr 01; 520:E3-E5. doi: 10.1038/nature14039
Richard Dodel, Axel Rominger, Peter Bartenstein, Frederik Barkhof, Kaj Blennow, Stefan Förster, Yaroslav Winter, Jan-Philipp Bach, Julius Popp, Judith Alferink, Jens Wiltfang, Katharina Buerger, Markus Otto, Piero Antuono, Michael Jacoby, Ralph Richter, James Stevens, Isaac Melamed, Jerome Goldstein, Stefan Haag, Stefan Wietek, Martin Farlow, Frank Jessen. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: A phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. The Lancet Neurology. 2013 Feb 28; 12:233-243. doi: 10.1016/S1474-4422(13)70014-0


Thursdays 1:30-4:30 pm

Patients +49 800-7799001

(free of charge)

Professionals +49 180-779900

(9 Cent/Min. German landline, mobile and out of Germany possibly more expensive)

Welcome to our website, here you can inform yourself basically cookie-free.

We would be pleased if you would allow a cookie to be set for analysis purposes in order to optimise our provided information. All data are pseudonymous and are only used by the DZNE. We deliberately avoid third-party cookies. You can deselect this setting at any time here.

Your browser allows the setting of cookies: